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ABSTRACT Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disorder leading to chronic
upper and lower airway disease. Fundamental data on epidemiology, clinical presentation, course and
treatment strategies are lacking in PCD. We have established an international PCD registry to realise an
unmet need for an international platform to systematically collect data on incidence, clinical presentation,
treatment and disease course.
The registry was launched in January 2014. We used internet technology to ensure easy online access
using a web browser under www.pcdregistry.eu. Data from 201 patients have been collected so far. The
database is comprised of a basic data form including demographic and diagnostic information, and visit
forms designed to monitor the disease course.
To establish a definite PCD diagnosis, we used strict diagnostic criteria, which required two to three diagnostic
methods in addition to classical clinical symptoms. Preliminary analysis of lung function data demonstrated a
mean annual decline of percentage predicted forced expiratory volume in 1 s of 0.59% (95% CI 0.98–0.22).
Here, we present the development of an international PCD registry as a new promising tool to advance
the understanding of this rare disorder, to recruit candidates for research studies and ultimately to
improve PCD care.
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ORIGINAL ARTICLE
PRIMARY CILIARY DYSKINESIA
Introduction
Primary ciliary dyskinesia (PCD (Online Mendelian Inheritance in Man: 244400)) is a rare autosomal
recessive disorder of ciliary motility resulting in chronic upper- and lower-airway disease. Organ laterality
defects occur in ∼40–50% of cases, usually situs inversus totalis (the condition is then known as
Kartagener’s syndrome). PCD affects ∼1:20000 individuals with a reported prevalence of 1:4000 to <1:50
000 [1]. PCD is genetically heterogeneous. So far, mutations in 31 different genes have been identified to be
causative for this disorder [2–6] accounting for ∼60–70% of cases. Due to biological and phenotypical
heterogeneities, different diagnostic tests have to be combined to confirm a PCD diagnosis [5–7]. As access
to diagnostic facilities is scarce in many countries, PCD is under-diagnosed and diagnosed too late [1].
While tremendous progress has been made in recent years in unveiling the molecular mechanisms of the
disease [2, 3, 8–19], PCD management is still hampered by a lack of fundamental data on epidemiology,
clinical presentation, disease course and effects of different treatment strategies [4–6]. Patient registries are
well-known tools to assemble sufficient numbers of individuals with a rare disease to assess and monitor
patient data in a standardised and longitudinal way, and to recruit candidates for clinical research studies
[20, 21]. Patient data have been collected by PCD centres on national or regional levels, e.g. in Denmark,
UK, Switzerland, USA and Germany. These databases have proved indispensable in facilitating research
aimed at the identification of novel PCD variants. By contrast, epidemiological and clinical research requires
larger datasets of items collected in a highly standardised way. In order to better characterise the clinical
course, and improve the diagnosis and treatment of PCD patients, we have established an internet-based,
international PCD registry for systematic and longitudinal data collection. The goal of the registry is to
collect data on a large number of individuals to advance our understanding of the range of conditions
associated with PCD and the factors that contribute to health outcomes. The objectives of the present article
are to: 1) detail the scientific rationale used to implement the registry, 2) describe the methodological details
of registry design, patient recruitment, data collection and data management, 3) raise awareness of this novel
tool, and 4) report first data on lung function and methods used for establishing a PCD diagnosis.
Methods
Rationale and requirements for the PCD registry
The international PCD registry was established to realise a previously unmet research need as there was no
international platform to systematically collect data from PCD individuals on the incidence, clinical
presentation, treatment and course of the disease. Importantly, the registry does not only serve clinicians
and researchers, but also provides the opportunity for individuals to participate in research who have been
under-represented previously.
The aims of the PCD registry include specifically the collection of data about diagnostic certainty, health
status at time of diagnosis, progression of disease (including influence of specific management plans),
severe infections, colonisation with problem microbes, life expectancy, sex-specific differences
(e.g. fertility), subtypes with unique clinical course as well as quality of life.
To achieve high acceptance of the registry, the registry was designed in close collaboration with lead
clinicians and researchers in Europe and North America as well as European and North American PCD
support groups. As legal, data protection and ethical requirements vary widely within different countries,
electronic data collection is restricted to anonymised data.
Eligibility criteria and recruitment
The PCD patient registry is a longitudinal study. It recruits all prevalent diagnosed subjects with PCD and
all subsequent incident cases. Both children and adults with PCD are eligible. Patients who fulfil the
following diagnostic criteria are considered to have a definite PCD diagnosis: 1) clinical presentation
consistent with PCD and 2) consistent findings specific for PCD by at least two methods (high-frequency
video microscopy analysis (HVMA), transmission electron microscopy (TEM), immunofluorescence
microscopy (IF), low nasal nitric oxide concentration/production (nNO) or bi-allelic disease-causing
mutations by genotyping).
If only HVMA and nNO are abnormal, HVMA should be repeated at least three times and show the same
abnormal results each time. Given the complexity of diagnosing PCD, it is anticipated that not all patients
will meet these definite diagnostic criteria. Therefore, all individuals with typical clinical symptoms are
eligible to enter the registry. These cases are usually considered to have a probable (one abnormal
diagnostic test) or possible (no clearly abnormal test) PCD diagnosis with exceptions made on an
individual basis (e.g. identification of the same bi-allelic disease-causing mutations in a subject of a sibling
with a confirmed diagnosis).
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Patients are recruited by their medical care-givers who are assigned as a referring centre. Becoming a
referring centre involves meeting all necessary legal and ethical requirements, a process guided by the
registry management team. Entering individual patient data is possible after written informed consent has
been obtained by the patient or his/her legal guardians. Informed consent forms are kept by the referring
centre to ensure complete anonymity of data collected in the electronic registry. No information is retained
from participants who do not consent. Participants can withdraw their authorisation for participation in
the study at any time.
All protocols for data collection and informed consent have been approved by the Ethical Review
Committees of the Medical Council Westfalen-Lippe and the Medical Faculty of the Westphalian
Wilhelms University Münster.
Item generation, programming of the registry database and data protection
Agreement on the items collected in the registry has been achieved by integrating input from
representatives of the US and several European PCD support groups. An internet-based data entry system
has been developed that provides plausibility checks. Furthermore, the system has been prepared to
integrate data from already existing local databases using suitable computer interfaces, thus avoiding the
need to enter similar data in two different databases. The database is securely located at the Institute of
Medical Biostatistics, Epidemiology and Informatics, Mainz (IMBEI), University Medical Centre Mainz,
Germany. This institute is responsible for maintenance, technical support and data protection of the
registry. Backup of data takes place daily using multiple servers. The registry is protected against misuse by
various security measures, such as firewall protection, encrypted data transfer and password-protected
access to the database. Except for the administration team, each contributor only has direct access to his/
her own data. A master list containing information that links the subject ID to identifying patient data is
not collected in the PCD registry. Such a list is kept peripherally by the referring centres.
Quality assurance
To ensure a high level of data quality, a three-step quality assurance process is employed that complements
plausibility checks provided by the registry software with two steps of manual control. 1) Data entry
performed by each centre’s operators is supported by the registry’s automatic validation routines. 2) All
nine forms that constitute a questionnaire are reviewed and explicitly finalised (“signed”) by the operator.
3) These finalised forms are reviewed again by the registry administrator team. Only forms that have
passed all three checks are considered valid and included in subsequent evaluations.
Data utilisation and sharing plan
Annual registry reports will be prepared using standard statistical software. A detailed description of all
relevant outcome parameters will be given applying descriptive statistical methods, i.e. frequency tables,
location and scale statistics and graphical presentations. Investigators interested in accessing registry data
or in recruiting registry participants for research studies are invited to contact the registry’s steering
committee. Short concept proposals can be submitted which will be discussed for feasibility and scientific
impact by the registry steering committee. Importantly, utilisation of patient data always requires explicit
written approval by the referring centres who have provided data and, if not covered by the signed
informed consent for the registry, by the affected PCD subjects.
Statistical analysis
SPSS 22 (www.ibm.com) and Prism 6 (www.graphpad.com) were employed to calculate all statistics and to
summarise the demographic characteristics of participants.
Results
Registry items
The database is comprised of a basic data form (table 1) including demographic and diagnostic
information, and seven visit forms (table 2) covering items to monitor the disease course. While basic data
are changed only when applicable, visit data are updated regularly (visit data can be entered at every visit;
yearly updates are requested). A diagram of the registry design is given in figure 1.
Registry items include age at diagnosis, family history (consanguinity), associated malformations/diseases,
laterality defects, clinical manifestations (otitis media, rhinosinusitis, pneumonia, bronchiectasis, neonatal
respiratory distress syndrome), microbiological results, diagnostic findings (HVMA, TEM, nNO, IF,
genotype), lung function, radiological findings and therapeutic measures (inhalation, antibiotics, oxygen,
ventilation, ENT surgery, lung surgery). Furthermore, quality-of-life assessment using QOL-PCD,
i.e. age-appropriate PCD-specific patient-reported outcome questionnaires developed in another BESTCILIA
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work package (www.bestcilia.eu), will be incorporated in the database as soon as validation in different
languages is completed.
Enrolment and demographic characteristics
The registry was launched in January 2014 (www.clinicaltrials.gov: NCT02419365). It is accessible via a
web browser under www.pcdregistry.eu. So far, data from 201 patients from five referring centres have
been collected in the database. Recruitment rates increased gradually from one patient in the first month
to a maximum of 46 patients in January 2015 (figure 2). As it is also possible to enter retrospective data,
data for more than one visit have been provided for 36/201 individuals. Gender distribution was 110
(54.7%) females and 91 (45.3%) males. Out of the 201 individuals, 98 (48.8%) were under 18 years old
and 103 (51.3%) were adults. The median age of participants was 18 years with a range from 1 month to
76 years. The age distribution is shown in figure 3.
Establishment of PCD diagnosis
Individuals were classified as having a definite, probable or possible PCD diagnosis as described in the
eligibility criteria in the Methods section. Out of 201 individuals, 123 had a definite diagnosis, 33 were graded
as subjects with a probable PCD diagnosis and 45 were assigned to have a possible PCD diagnosis (figure 4).
Diagnostic tests used for PCD work-up included nNO, HVMA, TEM, IF and genetic analysis (figure 5).
HVMA was most commonly used (144 individuals, 70%) and was abnormal in 140 individuals. HVMA
TABLE 1 Basic registry data: items collected at baseline; new information is added when
appropriate
Field Items
Administrative data Written informed consent
Patient identification; centre identification
Birth month, birth year
Gender
Ethnic origin
Socioeconomic background: level of education
(parents and patient)
Family history Parental consanguinity
Affected siblings
Other affected family members
Symptoms leading to diagnosis History of neonatal respiratory distress syndrome
Situs inversus totalis
Chronic rhinitis/rhinosinusitis
Chronic/recurrent otitis media
Chronic wet cough
Chronic/recurrent lower airways infection
Chronic atelectasis
Heterotaxia
Congenital heart defect
Cystic kidney disease
Hearing loss
Male infertility
Hydrocephalus internus
Retinitis pigmentosa
Male fertility Number of children, semen analysis, use of assisted
reproductive technologies
Female fertility Number of pregnancies, number of miscarriages,
number of ectopic pregnancies, number of children,
use of assisted reproductive technologies
Primary ciliary dyskinesia diagnostics Age, length/height and weight at diagnosis
Nasal nitric oxide measurement
High-frequency video microscopy findings
Transmission electron microscopy analysis
High-resolution immunofluorescence findings
Genetic results
All items contain the input option: not done, not available or not relevant.
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was scored normal only in four individuals (2%). All these four individuals fell into the category of
possible PCD diagnosis. Among the 142 subjects with nNO testing, 10 individuals (5%) exhibited normal
results. Three of these subjects with normal nNO values were rated as having a definitive PCD diagnosis
based on other tests. TEM showed normal results in 30 out of 119 tested individuals (25.2%). IF was
performed in 69 individuals. In 48 patients, IF showed clearly abnormal findings, whereas IF staining was
normal in 21 individuals. Of note, the number of antibodies, which correlates with the sensitivity of the
method, used for IF varied from two to six. Genetic results were available in a subset of 40 individuals, 30
of which displayed bi-allelic disease-causing mutations.
The number of diagnostic tests used in each patient is given in figure 5f. The majority of individuals had
two (n=50; 25%) or three (n=61; 30%) tests.
Lung function in PCD
In a subset of 71 individuals with definite PCD, lung function data have already been cleared (figure 6).
Linear regression of percentage predicted forced expiratory volume in 1 s (FEV1 % pred) values versus age
exhibited a mean annual decline of 0.59% (p=0.0025; 95% CI 0.98–0.22). Mean percentage predicted
forced vital capacity (FVC % pred) decline was 0.39% per year, which was not statistically significantly
TABLE 2 Visit data items collected at least yearly
Field Items
Anthropometric data Height/length and weight at visit date
Lung function Spirometry (FVC, FEV1, MEF25%, MEF25–75%)
6MWD
Multiple-breath washout (LCI, FRCmbw)
Blood gas analysis (pH, carbon dioxide tension, HCO3
–,
base excess, oxygen tension, oxygen saturation)
Oxygen saturation (pulse oximetry)
Imaging Chest radiograph
Chest computed tomography
Chest magnetic resonance imaging
Radioaerosol mucociliary clearance analysis
Clinical disease manifestation Lower airways: haemoptysis (more than traces),
infectious exacerbations, pneumothorax
Upper airways: otitis media, hearing impairment,
sinusitis, chronic rhinitis, nasal polyps
Other conditions: gastro-oesophageal reflux,
sinus headache, chest pain
Microbiological findings Sputum, throat swab, cough swab, laryngeal swab, nasal swab,
nasal lavage, bronchoalveolar lavage, ear swab
Therapy Antibiotics: systemic, inhaled
Inhalation therapy (not antibiotics): NaCl 0.9%, hypertonic
NaCl (at least 3%), bronchodilator, corticosteroids, other
Other drugs
Physiotherapy/airways clearance therapy: postural drainage and
percussion, autogenic drainage, positive expiratory pressure,
active-cycle breathing technique, oscillatory positive
expiratory pressure, high-frequency chest compression,
exercise training
Oxygen therapy: intermittent/continuous
Long-term mechanical ventilation: noninvasive/invasive
Lung surgery: lobectomy, lung transplantation, other
Upper-airway surgery: tympanostomy tube insertion,
adenotomy, sinus surgery, mastoidectomy, other
Quality of life: the PCD-specific quality of life questionnaire
(QOL-PCD) will be added as soon as validation
has been completed
All items contain the input option: not done, not available or not relevant. Users can choose between this
extended dataset and a limited dataset with fewer variables. FVC: forced vital capacity; FEV1: forced expiratory
volume in 1 s; MEF25%: mid-expiratory flow at 25% of FVC; MEF25–75%: mid-expiratory flow at 25–75% of FVC;
6MWD: 6-min walking distance; LCI: lung clearance index; FRC: functional residual capacity; PCD: primary
ciliary dyskinesia.
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different from zero (p=0.0851; 95% CI 0.83–0.06). Compared with published data [22], our cohort showed
a similar decline of FEV1 % pred. As our FEV1 % pred data did not differ significantly from MARTHIN
et al. [22] (Mann–Whitney test, p=0.3570), we pooled data from both studies and calculated a yearly
decline of FEV1 % pred of 0.72% in this cohort of 142 individuals (p<0.0001; 95% CI 0.98–0.46).
PCD REGISTRY
Data entry initially, 
update when 
applicable
Update yearly
Month/year of birth
Basic data
Symptoms leading 
to diagnosis
PCD diagnostics
Fertility
Sex
Ethnic origin
Education
Family history
TEM
IF
Genetics
nNO
HVMA
Anthropometry
Visit data
Therapy
Quality of life
Lung function
Imaging
Clinical symptoms
Microbiology
FIGURE 1 Primary ciliary dyskinesia (PCD) registry design. The database is comprised of a basic data form
that is completed at recruitment and changed only when applicable. Visit data are updated at least once a
year. nNO: nasal nitric oxide production rate/concentration; HVMA: high-frequency video microscopy analysis;
TEM: transmission electron microscopy; IF: immunofluorescence microscopy.
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FIGURE 2 Recruitment of patients per month from January 2014 to July 2015. Total participants n=201.
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Discussion
PCD is a rare congenital respiratory disorder presenting to clinicians and patients with numerous
uncertainties. As robust data describing disease severity and course are largely lacking, management has to
rely on small retrospective, cross-sectional case series and experiences in disorders such as cystic fibrosis or
non-cystic fibrosis bronchiectasis. This approach, however, is unsafe, because it neglects differences in the
pathophysiology of these diseases. Therefore, we have established an international PCD registry to address
the urgent need to systematically assess epidemiological, clinical and psychological parameters associated
with PCD and its management in a sufficient number of individuals. This will not only give a detailed
picture of the current disease status, but will also identify effects of changes in PCD diagnostics and
treatment. Furthermore, the registry will facilitate the interconnection of PCD centres, and will serve as a
tool to identify and recruit suitable individuals for research studies.
A main strength of the registry is its collaborative development. Selection of registry items has not only
been agreed on among participating centres, but has also been harmonised with patient organisations,
including the North American PCD Foundation. Therefore, it is guaranteed that information collected in
the registry will be highly relevant and that the patient’s perspective is appropriately represented.
In order to achieve the highest possible acceptance, we took particular care to create a user-friendly
environment. Data entry is possible via a standard web browser. Thus, there is no need to install
additional software. As part of the data security plan, access to the database is provided via user-specific
accounts that allow tracking back any change in the database to the responsible person. Users of a given
centre only have access to patient data of their own centre.
A unique feature of the registry is the assessment of quality of life as an important patient reported
outcome measure. Currently, PCD-specific quality-of-life questionnaires (QOL-PCD) in different languages
FIGURE 3 Age distribution of
individuals. Total participants n=201.
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are being validated [23]. As soon as this process is completed in the different languages represented in the
registry, these questionnaires will be incorporated in the registry. Therefore, we will include a sensitive tool
to measure symptoms, functioning and quality of life on a routine basis [24].
a) b)
c) d)
e) f)
Normal Abnormal Not available Normal Abnormal Not available
 
 
 
 
 
 
 
Normal Abnormal Not available
Normal Abnormal Not available
No abnormal test
2 abnormal tests
4 abnormal tests
1 abnormal test
3 abnormal tests
5 abnormal tests
Normal Abnormal Not available
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
15; 7%
48; 24%
140; 70%
57; 28%
4; 2%10; 5%
59; 29%
132; 66%
42; 21%
21; 10%
30; 15%
50; 25%
61; 30%
24; 12%
9; 5%
10; 5%
30; 15%
89; 44%
82; 41%
132; 66%
161; 80%
FIGURE 5 Number and percentage of normal and abnormal test results using different methods. a) Nasal
nitric oxide production rate/concentration. b) High-frequency video microscopy analysis. c) Transmission
electron microscopy. d) Immunofluorescence microscopy. e) Genetic identification of bi-allelic
disease-causing mutations. f ) Number and percentage of individuals with zero, one, two, three four and five
abnormal test results. Results from all five tests were available only in a subset of individuals. In most
subjects, findings from two to three tests were available.
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A potential concern for patient self-reported registries is inaccuracy of data. Therefore, we have chosen a
clinician-driven data entry system. Confirmation of diagnosis is particularly difficult in PCD because of
the high number of genetic and phenotypic subtypes requiring different combinations of methods to
establish a diagnosis coupled with limited access to diagnostic services in many countries. In order to
reach a high level of diagnostic certainty, we have included all different methods currently used for PCD
work-up and established an algorithm to classify cases as confirmed, probable or possible. Furthermore,
collaboration of centres within the network will result in a transition of probable or possible to confirmed
cases in many instances where limited diagnostic facilities are the main obstacle.
As a limitation, the registry design does not enable patients to directly enter data and therefore a number
of patients might not be recruited because they are not cared for by a registry centre. Equally, we cannot
approach patients directly who qualify for participation in clinical trials because only strictly anonymised
data are stored in the registry database. However, we strongly believe that these limitations are outweighed
by the high level of data security that we have achieved in our registry and we ensure patient participation
by closely cooperating with patient support groups.
Another reason for a clinician-driven registry is that the data entry system is in the English language. As
clinicians and scientists are used to English as the language of medicine, we decided against different
language versions. Only QOL-PCD questionnaires will be provided in different languages because these
questions will be answered by the patients directly.
Data collection in the registry is not population-based and therefore data might not be representative.
However, an international population-based registry for such a rare disorder cannot aim to assemble a
high number of individuals internationally.
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FIGURE 6 Linear regression of lung function parameters versus age. a) Percentage predicted forced expiratory volume in 1 s (FEV1 % pred) and b)
percentage predicted forced vital capacity (FVC % pred) were calculated using Global Lung Function Initiative 2012 equations [32]. c) Comparison
of FEV1 % pred values versus age with published data [22] shows a similar decline.
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Clearing of data entered into the registry is currently under way. We report which methods were used for
establishing a PCD diagnosis in figure 4. nNO testing and HVMA were performed most frequently. Both
methods exhibited a very low proportion of false-negative test results. nNO was normal in three
individuals with a definite PCD diagnosis, a fact that underlines that PCD cannot be ruled out by
demonstration of normal nNO values alone [25, 26]. HVMA was only normal in individuals who fell into
the category of having a possible PCD diagnosis, i.e. some of these four subjects might in fact not be
affected by PCD. Of note, we do not have information about the number of individuals 1) with abnormal
HVMA findings due to secondary ciliary dyskinesia who were not enrolled into the registry because PCD
was excluded by other means or 2) who were not enrolled because of false-normal HVMA findings in
phenotypic variants known to be difficult to diagnose by HVMA [2, 3, 7, 11, 12, 27]. Thus, it is not
possible to deduce the true sensitivity or specificity of HVMA based on our findings. However, the high
proportion of normal TEM findings clearly demonstrates the limited sensitivity of that method in
diagnosing the whole spectrum of PCD variants [11, 12, 19, 27, 28]. Identification of ciliary protein
mislocalisation by IF requires the use of several antibodies targeting different ciliary components [2, 3, 12,
15, 19, 29]. In the registry, IF data were available for a subset of patients. The number of antibodies used
in individual patients ranged from two to six. Therefore, the sensitivity of IF might have been higher in
subjects with normal IF testing if additional antibodies would have been used for analysis. Bi-allelic
disease-causing mutations have been identified in 30 subjects, a number we expect to grow quickly as a
result of the increasing use of high-throughput sequencing techniques.
Diagnostic tests recommended for PCD work-up include nNO, HVMA, TEM, IF and genetic analysis
[30]. In the majority of subjects, two to three methods were sufficient for a definite PCD diagnosis. 57
individuals had only one or no abnormal test result. These individuals require additional diagnostic efforts
to further clarify their disease status, a process now facilitated by the network of different centres
collaborating in the registry.
Lung function parameters are key outcome determinants in PCD. Here, we report a decline of FEV1 %
pred with age that is similar to previous reports [22, 31]. Pooling our registry data with those published by
MARTHIN et al. [22] yielded a mean annual FEV1 % pred decline of 0.72% based on a relatively large
cohort of 142 PCD patients. FVC % pred values exhibited a slight annual decline that did not reach
statistical significance. Possibly, this is related to the small sample size and will change in the future after
incorporation of additional data. Nevertheless, our data support that, in general, PCD lung disease follows
more an obstructive than a restrictive pattern.
During the first months of operation, the registry recruited a considerable number of PCD individuals. Of
course, we aim to incorporate a much larger number of individuals, not only from BESTCILIA consortium
members, but also from other countries. Therefore, we strongly encourage PCD centres worldwide to
participate. While the registry is currently run by BESTCILIA members, we are already working on its
future structural reorganisation: with an increasing number of participants, it will become impracticable for
a single registry administration to monitor all data entered into the registry. Therefore, regional or national
subdivisions will be defined that nominate delegates as data administrators and members of the registry
steering committee. Naturally, these subdivisions will not be static, i.e. centres from new regions will have
the opportunity to designate their own administrators.
In summary, we report the establishment of a comprehensive international registry for PCD as a new
promising tool to better understand this rare disorder. Active participation in this registry is highly welcome.
For further details and contact information, please refer to the registry homepage www.pcdregistry.eu.
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